Advertisement

Pancreatic Cancer

  • Carsten Nieder
  • Thomas B. Brunner
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

Treatment of pancreatic cancer is challenging. Both delayed diagnosis, locoregional disease extension, likelihood of local relapse and distant metastases contribute to disappointing outcome. Many patients are not amenable to curative surgical resection. Controversy exists around role and concepts of neoadjuvant and adjuvant chemo- and chemoradiation in common ductal adenocarcinoma scenarios, regarding both resectable and borderline resectable disease. Palliative treatment including chemoradiation and stereotactic body radiotherapy continues to evolve. The focus of this chapter is prognostic and predictive models for patients with ductal adenocarcinoma.

Keywords

Overall Survival Pancreatic Cancer Stereotactic Body Radiotherapy Radiation Therapy Oncology Group Advanced Pancreatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Anonymous (1979) A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg 189:205–208Google Scholar
  2. Anonymous (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 59:2006–2010CrossRefGoogle Scholar
  3. Belka C, Nieder C, Molls M (2006) Biological basis of combined radio- and chemotherapy. In: Brown JM, Mehta MP, Nieder C (eds) Multimodal concepts for integration of cytotoxic drugs and radiation therapy Springer Heidelberg. New York, Berlin, pp 3–18CrossRefGoogle Scholar
  4. Ben-Josef E, Schipper M et al (2012) A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 84:1166–1171PubMedCentralPubMedCrossRefGoogle Scholar
  5. Berger AC, Garcia M Jr et al (2008) Postresection CA 19–9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 26:5918–5922PubMedCentralPubMedCrossRefGoogle Scholar
  6. Bjerregaard JK, Mortensen MB et al (2012) Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 83:909–915PubMedCrossRefGoogle Scholar
  7. Bjerregaard JK, Mortensen MB et al (2013) Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients. Eur J Cancer 49:98–105PubMedCrossRefGoogle Scholar
  8. Blackstock A, Tempero M et al (2001) Cancer and Leukemia Group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with localoregional adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 51:31 abst #49Google Scholar
  9. Blackstock AW, Bernard SA et al (1999) Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17:2208–2212PubMedGoogle Scholar
  10. Brennan MF, Kattan MW et al (2004) Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 240:293–298PubMedCentralPubMedCrossRefGoogle Scholar
  11. Breslin TM, Hess KR et al (2001) Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8:123–132PubMedCrossRefGoogle Scholar
  12. Brunner TB, Scott-Brown M (2010) The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol 5:64PubMedCentralPubMedCrossRefGoogle Scholar
  13. Brunner TB, Sauer R et al (2011) Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients. Radiat Oncol 6:88PubMedCentralPubMedCrossRefGoogle Scholar
  14. Callery MP, Chang KJ et al (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16:1727–1733PubMedCrossRefGoogle Scholar
  15. Cardenes HR, Moore AM et al (2011) A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study. Am J Clin Oncol 34:460–465PubMedCrossRefGoogle Scholar
  16. Chang DT, Schellenberg D et al (2009) Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 115:665–672PubMedCrossRefGoogle Scholar
  17. Chauffert B, Mornex F et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19:1592–1599PubMedCrossRefGoogle Scholar
  18. Choi M, Heilbrun LK et al (2010) Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol 33:257–261PubMedGoogle Scholar
  19. Chuong MD, Springett GM et al (2013) Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 86:516–522PubMedCrossRefGoogle Scholar
  20. Cohen SJ, Dobelbower R Jr et al (2005) A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62:1345–1350PubMedCrossRefGoogle Scholar
  21. Corsini MM, Miller RC et al (2008) Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975–2005). J Clin Oncol 26:3511–3516PubMedCrossRefGoogle Scholar
  22. Crane CH, Winter K et al (2009) Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 27:4096–4102PubMedCentralPubMedCrossRefGoogle Scholar
  23. Crane CH, Varadhachary GR et al (2011) Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29:3037–3043PubMedCentralPubMedCrossRefGoogle Scholar
  24. de Castro SM, Biere SS et al (2009) Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreas. Br J Surg 96:417–423PubMedCrossRefGoogle Scholar
  25. Didolkar MS, Coleman CW et al (2010) Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg 14:1547–1559PubMedCrossRefGoogle Scholar
  26. Edge SB, Byrd DR et al (2010). American joint committee on cancer, American Cancer Society. AJCC Cancer Staging Manual. 7th edn. Berlin, SpringerGoogle Scholar
  27. Estrella JS, Rashid A et al (2012) Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 118:268–277PubMedCrossRefGoogle Scholar
  28. Gillen S, Schuster T et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267PubMedCentralPubMedCrossRefGoogle Scholar
  29. Girard N, Mornex F et al (2010) Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial. Int J Radiat Oncol Biol Phys 77:1426–1432Google Scholar
  30. Golcher H, Brunner T et al (2008) Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol 34:756–764PubMedCrossRefGoogle Scholar
  31. Goodman KA, Regine WF et al (2012) Radiation therapy oncology group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys 83:901–908PubMedCrossRefGoogle Scholar
  32. Gurka MK, Collins SP et al (2013) Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiat Oncol 8:44PubMedCentralPubMedCrossRefGoogle Scholar
  33. Habermehl D, Kessel K et al (2012) Neoadjuvant chemoradiation with gemcitabine for locally advanced pancreatic cancer. Radiat Oncol 7:28PubMedCentralPubMedCrossRefGoogle Scholar
  34. Herman JM, Wild AT et al (2013) Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol 31:886–894PubMedCrossRefGoogle Scholar
  35. Huguet F, André T et al (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326–331PubMedCrossRefGoogle Scholar
  36. Huguet F, Goodman KA et al (2012) Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations. Int J Radiat Oncol Biol Phys 83:1355–1364PubMedCrossRefGoogle Scholar
  37. Jackson AS, Jain P et al (2010) Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer. Clin Oncol (R Coll Radiol) 22:570–577CrossRefGoogle Scholar
  38. Jingu K, Tanabe T et al (2012) Intraoperative radiotherapy for pancreatic cancer: 30-year experience in a single institution in Japan. Int J Radiat Oncol Biol Phys 83:e507–e511PubMedCrossRefGoogle Scholar
  39. Katz MH, Marsh R et al (2013). Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013 Feb 23Google Scholar
  40. Kelly P, Das P et al (2013) Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 85:e143–e149PubMedCrossRefGoogle Scholar
  41. Kim EJ, Ben-Josef E et al (2013). A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 2013 May 29Google Scholar
  42. Kimple RJ, Russo S et al (2012) The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Rev Anticancer Ther 12:469–480PubMedCentralPubMedCrossRefGoogle Scholar
  43. Klaassen DJ, MacIntyre JM et al (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil–an Eastern Cooperative Oncology Group study. J Clin Oncol 3:373–378PubMedGoogle Scholar
  44. Klinkenbijl JH, Jeekel J et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230: 776–82; discussion 782–4Google Scholar
  45. Koong AC, Le QT et al (2004) Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 58:1017–1021PubMedCrossRefGoogle Scholar
  46. Laurence JM, Tran PD et al (2011) A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 15:2059–2069PubMedCrossRefGoogle Scholar
  47. Li C-P, Chao Y et al (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57:98–104PubMedCrossRefGoogle Scholar
  48. Loehrer PJ Sr, Feng Y et al (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105–4112PubMedCentralPubMedCrossRefGoogle Scholar
  49. McGinn CJ, Zalupski MM et al (2001) Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19:4202–4208PubMedGoogle Scholar
  50. Micke O, Hesselmann S et al (2005) Results and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res 25:1523–1530PubMedGoogle Scholar
  51. Miller RC, Iott MJ, Corsini MM (2009) Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium. Int J Radiat Oncol Biol Phys 75:364–368PubMedCrossRefGoogle Scholar
  52. Moertel CG, Frytak S et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705–1710PubMedCrossRefGoogle Scholar
  53. Moghanaki D, Mick R et al (2011) Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma. JOP 12:438–444PubMedGoogle Scholar
  54. Murphy JD, Adusumilli S et al (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68:801–808PubMedCrossRefGoogle Scholar
  55. Murphy JD, Christman-Skieller C et al (2010) A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 78:1420–1426PubMedCrossRefGoogle Scholar
  56. Murphy JD, Chang DT et al (2012) Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer 118:1119–1129PubMedCrossRefGoogle Scholar
  57. Neoptolemos JP, Stocken DD et al (2001) Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234:758–768PubMedCentralPubMedCrossRefGoogle Scholar
  58. Neoptolemos JP, Stocken DD et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New Engl J Med 350:1200–1210PubMedCrossRefGoogle Scholar
  59. Parlak C, Topkan E et al (2012) Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiat Oncol 7:37PubMedCentralPubMedCrossRefGoogle Scholar
  60. Pipas JM, Mitchell SE et al (2001) Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 50:1317–1322PubMedCrossRefGoogle Scholar
  61. Pisters PW, Abbruzzese JL et al (1998) Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 16:3843–3850PubMedGoogle Scholar
  62. Polistina F, Costantin G et al (2010) Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 17:2092–2101PubMedCrossRefGoogle Scholar
  63. Regine WF, Winter KA et al (2011) Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 18:1319–1326PubMedCentralPubMedCrossRefGoogle Scholar
  64. Rich TA, Winter K et al (2012) Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer. Onco Targets Ther 5:161–170PubMedCentralPubMedCrossRefGoogle Scholar
  65. Rwigema JC, Parikh SD et al (2011) Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 34:63–69PubMedCrossRefGoogle Scholar
  66. Saif MW, Eloubeidi MA et al (2005) Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: Expression analysis of genes related to outcome. J Clin Oncol 23:8679–8687PubMedCrossRefGoogle Scholar
  67. Schellenberg D, Quon A et al (2010) 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 77:1420–1425PubMedCrossRefGoogle Scholar
  68. Schmidt J, Abel U et al (2012) Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 30:4077–4083PubMedCrossRefGoogle Scholar
  69. Showalter TN, Winter KA et al (2011) The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys 81:1328–1335PubMedCentralPubMedCrossRefGoogle Scholar
  70. Small W Jr, Berlin J et al (2008) Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol 26:942–947PubMedCrossRefGoogle Scholar
  71. Van Laethem JL, Hammel P et al (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 28:4450–4456PubMedCentralPubMedCrossRefGoogle Scholar
  72. Van Laethem JL, Verslype C et al (2012) New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol 23:570–576PubMedCrossRefGoogle Scholar
  73. White RR, Kattan MW et al (2006) Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram. Ann Surg Oncol 13:1485–1492PubMedCrossRefGoogle Scholar
  74. Willett CG, Safran H et al (2003) Clinical research in pancreatic cancer: The Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 56:31–37PubMedCrossRefGoogle Scholar
  75. Wolff RA, Evans DB et al (2001) Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7:2246–2253PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Oncology and Palliative MedicineNordland HospitalBodøNorway
  2. 2.Radiation OncologyUniversity Hospital FreiburgFreiburgGermany

Personalised recommendations